Cargando…

Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic

Anaphylaxis is a rare side-effect of COVID-19 vaccines. To (a) provide direct advice and reassurance to certain persons with a history of anaphylaxis/complex allergy, in addition to that available in national guidelines, and (b) to provide a medically supervised vaccination, a specialist regional va...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyons, Daniel, Murray, Cliodhna, Hannigan, Siobhan, Sui, Jacklyn, Alamin, Salma, Conlon, Niall, Keogan, Mary, Khalib, Khairin, Fitzpatrick, Chris, O’B Hourihane, Jonathan, Carey, Michael, Edgar, J David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278227/
https://www.ncbi.nlm.nih.gov/pubmed/35753019
http://dx.doi.org/10.1093/cei/uxac064
_version_ 1784746147356606464
author Lyons, Daniel
Murray, Cliodhna
Hannigan, Siobhan
Sui, Jacklyn
Alamin, Salma
Conlon, Niall
Keogan, Mary
Khalib, Khairin
Fitzpatrick, Chris
O’B Hourihane, Jonathan
Carey, Michael
Edgar, J David M
author_facet Lyons, Daniel
Murray, Cliodhna
Hannigan, Siobhan
Sui, Jacklyn
Alamin, Salma
Conlon, Niall
Keogan, Mary
Khalib, Khairin
Fitzpatrick, Chris
O’B Hourihane, Jonathan
Carey, Michael
Edgar, J David M
author_sort Lyons, Daniel
collection PubMed
description Anaphylaxis is a rare side-effect of COVID-19 vaccines. To (a) provide direct advice and reassurance to certain persons with a history of anaphylaxis/complex allergy, in addition to that available in national guidelines, and (b) to provide a medically supervised vaccination, a specialist regional vaccine allergy clinic was established. The main objective was to determine if risk stratification through history can lead to safe COVID-19 vaccination for maximum population coverage. A focused history was taken to establish contraindications to giving COVID-19 vaccines. People who reported a high-risk allergy history were given a vaccine not containing the excipient thought to have directly caused previous anaphylaxis. All vaccines were monitored for 30 min after administration. A total of 206 people were vaccinated between 6 July 2021 and 31 August 2021; Comirnaty (Pfizer-BioNTech) (n = 34), and Janssen (n = 172). In total, 78% were women. Ninety-two people (45%) reported a high-risk allergy history. There were no cases of anaphylaxis. Three people developed urticaria and one of these also developed transient tachycardia. One vaccinee developed a pseudoseizure. Two of 208 people (<1%) referred during this time declined vaccination based on personal preference, despite the assessment of low clinical risk. In our experience, all vaccines with high-risk allergy histories were administered Pfizer BioNTech or Janssen Covid-19 vaccines uneventfully following screening based on allergy-focussed history. Our data support that drug allergy is not associated with a higher risk of vaccine-related anaphylaxis but may act to guide the administration of alternate vaccines to people with polyethylene glycol/polysorbate 80/trometamol allergies or anaphylaxis after the first dose.
format Online
Article
Text
id pubmed-9278227
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92782272022-07-18 Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic Lyons, Daniel Murray, Cliodhna Hannigan, Siobhan Sui, Jacklyn Alamin, Salma Conlon, Niall Keogan, Mary Khalib, Khairin Fitzpatrick, Chris O’B Hourihane, Jonathan Carey, Michael Edgar, J David M Clin Exp Immunol Research Articles Anaphylaxis is a rare side-effect of COVID-19 vaccines. To (a) provide direct advice and reassurance to certain persons with a history of anaphylaxis/complex allergy, in addition to that available in national guidelines, and (b) to provide a medically supervised vaccination, a specialist regional vaccine allergy clinic was established. The main objective was to determine if risk stratification through history can lead to safe COVID-19 vaccination for maximum population coverage. A focused history was taken to establish contraindications to giving COVID-19 vaccines. People who reported a high-risk allergy history were given a vaccine not containing the excipient thought to have directly caused previous anaphylaxis. All vaccines were monitored for 30 min after administration. A total of 206 people were vaccinated between 6 July 2021 and 31 August 2021; Comirnaty (Pfizer-BioNTech) (n = 34), and Janssen (n = 172). In total, 78% were women. Ninety-two people (45%) reported a high-risk allergy history. There were no cases of anaphylaxis. Three people developed urticaria and one of these also developed transient tachycardia. One vaccinee developed a pseudoseizure. Two of 208 people (<1%) referred during this time declined vaccination based on personal preference, despite the assessment of low clinical risk. In our experience, all vaccines with high-risk allergy histories were administered Pfizer BioNTech or Janssen Covid-19 vaccines uneventfully following screening based on allergy-focussed history. Our data support that drug allergy is not associated with a higher risk of vaccine-related anaphylaxis but may act to guide the administration of alternate vaccines to people with polyethylene glycol/polysorbate 80/trometamol allergies or anaphylaxis after the first dose. Oxford University Press 2022-06-26 /pmc/articles/PMC9278227/ /pubmed/35753019 http://dx.doi.org/10.1093/cei/uxac064 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://academic.oup.com/pages/standard-publication-reuse-rightsThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
spellingShingle Research Articles
Lyons, Daniel
Murray, Cliodhna
Hannigan, Siobhan
Sui, Jacklyn
Alamin, Salma
Conlon, Niall
Keogan, Mary
Khalib, Khairin
Fitzpatrick, Chris
O’B Hourihane, Jonathan
Carey, Michael
Edgar, J David M
Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic
title Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic
title_full Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic
title_fullStr Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic
title_full_unstemmed Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic
title_short Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic
title_sort risk stratification through allergy history: single-centre experience of specialized covid-19 vaccine clinic
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278227/
https://www.ncbi.nlm.nih.gov/pubmed/35753019
http://dx.doi.org/10.1093/cei/uxac064
work_keys_str_mv AT lyonsdaniel riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT murraycliodhna riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT hannigansiobhan riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT suijacklyn riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT alaminsalma riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT conlonniall riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT keoganmary riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT khalibkhairin riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT fitzpatrickchris riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT obhourihanejonathan riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT careymichael riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic
AT edgarjdavidm riskstratificationthroughallergyhistorysinglecentreexperienceofspecializedcovid19vaccineclinic